U.S. Markets closed

Johnson & Johnson (JNJ)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
161.98-3.24 (-1.96%)
At close: 4:00PM EDT
Sign in to post a message.
  • R
    Rob
    U.S. authorizes another batch of Johnson & Johnson’s Covid-19 vaccine, a reported 14 million doses
    JNJ is the only shot you should get!
    Dad Says Life ‘Not the Same’ for 21-Year-Old Student Who Developed Myocarditis After Second Moderna Shot
    A New Jersey student whose college, the New Jersey Institute of Technology, requires all students to be fully vaccinated in order to attend classes in the fall became ill within hours of receiving the second dose of Moderna’s COVID vaccine.
    Bullish
  • K
    Keith
    Great long term investment with a nice dividend.
  • R
    Rob
    JNJ is the only shot you should get!
    *Pfizer Skipped Critical Testing and Cut Corners on Quality Standards for Covid Vaccine
    Information obtained by Trial Site News reveals that routine quality testing issues were overlooked in the rush to authorise the use of the Pfizer/BioNTech COVID-19 vaccine and that governments around the globe, including the US and UK government, conducting a massive vaccination program with a completely experimental vaccine.

    The documents appeared to show that Pfizer did not thoroughly investigate the biodistribution and pharmacokinetics of its vaccine before submitting it to the European Medicines Agency (EMA) for review.


    In key studies – known as biodistribution studies, which are designed to determine where an injected compound travels within the body, and which tissues or organs it accumulates in – Pfizer did not use the commercial vaccine (BNT162b2) but instead used a surrogate mRNA that produced the luciferase protein.

    The EMA reviewers even shared an explicit admission that: “No traditional pharmacokinetic or biodistribution studies have been performed with the vaccine candidate BNT162b2.”


    Pharmacokinetics refers to how the body uses a drug, what it does with it, and how the drug travels through the body. This involves the time course of its absorption, bioavailability, distribution, metabolism, and excretion.

    According to Trial Site News, regulatory documents show that Pfizer did not follow industry-standard quality management practices during preclinical toxicology studies during vaccines, as key studies failed to meet good laboratory practice (GLP).


    Good Laboratory Practice or GLP is the quality system that is concerned with the quality and integrity of non-clinical studies. It aims to “ensure the consistency, reliability, uniformity, and quality of chemical non-clinical safety tests.” GLP is most commonly associated with the pharmaceutical industry and non-clinical animal testing that must be performed before new drug products can be approved.

    Additionally, the full panel of industry-standard reproductive toxicity and genotoxicity studies were not performed.


    TrialSite founder and CEO Daniel O’Connor, said: “The implications of these findings are that Pfizer was trying to accelerate the vaccine development timeline based on the pressures of the pandemic.


    “The implications of these findings are that Pfizer was trying to accelerate the vaccine development timeline based on the pressures of the pandemic.”

    O’Connor said that in the case of the Pfizer vaccine, Pfizer was “given more discretion even with a radically new life-science based technology.”

    When new drugs are submitted, it is standard for the EMA to disclose its assessment, however, in the case of the Pfizer vaccine, the EMA did not disclose the results of Pfizer’s biodistribution studies in its public EMA summary.

    One of TrialSite’s sources noted the following:

    “A quick review the Toxicology Section (2.3.3) of The European Medicines Agency (EMA) Assessment Report on Comirnaty (COVID-19 mRNA vaccine) issued on 19 February 2021, raises concerns about data applicability of preclinical study findings to clinical use:

    To determine the biodistribution of the LNP-formulated modified mRNA (modRNA), the applicant did study distribution of the modRNA in two different non-GLP studies, in mice and rats, and determined the biodistribution of a surrogate luciferase modRNA.

    Thus, one might question the validity and applicability of non-GLP studies conducted using a variant of the subject mRNA vaccine.

    In addition, no genotoxicity data were provided to EMA.”

    With the vaccine rollout in full swing across the globe and children set to be vaccinated as early as August, it appears as though big pharma corporations such as Pfizer, Moderna, and co. have managed to rush through a completely experimental jab, which in the case of Pfizer, has not undergone industry-standard quality tests.
  • K
    Keith
    Great investment
  • T
    T.
    FDA approves request to extend the shelf-life of Johnson & Johnson's COVID-19 vaccine by 1.5 month
  • S
    Solomon
    Need to get litigation BS out of the board room and leave this up to the lawyers. All Pharma have legal issues with law suits. Law suites goes with the territory and will be a on going issue. Look at the pipeline. We could be like PFE and hold under 40 for 6 years and not move up. Been a JNJ holder for over 40 years and still holding.
  • R
    Rob
    CDC Admits Teens Vaccinated with Pfizer or Moderna at Higher Risk of Heart Inflammation
    In guidance quietly updated June 1, the Centers for Disease Control and Prevention said there is a higher-than-expected number of cases of myocarditis among young teens after the second dose of an mRNA COVID vaccine.
    Bullish
  • C
    Cracker Barrel Offends Me
    I've owner PFE for about a year and a half unfortunately...no grow at all just a div stock. Looking to jump in J&J. What is a good entry price?
  • S
    Sinan
    60 M doses, what was profit to JNJ per dose? $1? no reason for stock to fall 1.5%.
  • G
    G7man
    Wow good Divi great organization too
  • R
    Rob
    JNJ is safer! MRNA vaccine is bad!
    CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second MRNA Covid vaccine shot
    The number of cases of a heart inflammation condition in 16- to 24-year-olds was higher than expected after they received their second dose of Pfizer’s or Moderna’s Covid-19 vaccines, the CDC said.
    Total UK reactions for the experimental mRNA vaccine Tozinameran (code BNT162b2,Comirnaty) from BioNTech/ Pfizer: 6,732 deaths and 502,162 injuries to 05/06/2021
    There have been 275 reported cases of myocarditis or pericarditis, which are inflammation conditions involving the heart, in people ages 16 to 24 as of May 31, according to a CDC presentation.
  • s
    stadtler
    I’ve been day trading for years and I’m so glad I finally found (http://Pick-stocks.com). They’re pre-market watchlists cover all the latest market-moving news, and they don’t beat you down with tons of ads. Highly recommend!
  • L
    Leo
    I believe Johnson and Johnson stock will increase long term with the amount of drugs in the pipeline which can increase profits.
    Bullish
  • K
    Keith
    Good old faithful stock w nice dividend
  • K
    Keith
    Nice steady dividend and stock appreciation over time
  • T
    T.
    Total overreaction. Minus 3bn market cap because of a few 100 mln vaccine production costs
  • R
    Rob
    JNJ is definitely the safest shot.
    This week’s total VAERS data, from Dec. 14, 2020, to May 28, 2021, for all age groups show:
    17% of deaths were related to cardiac disorders.
    52% of those who died were male, 45% were female and the remaining death reports did not include gender of the deceased.
    The average age of death was 74.4.
    As of May 28, 1,831 pregnant women reported adverse events related to COVID vaccines, including 596 reports of miscarriage or premature birth.
    Of the 2,876 cases of Bell’s Palsy reported, 52% were reported after Pfizer vaccinations, 41% following vaccination with the Moderna vaccine and 253 cases, or 9%, of Bell’s Palsy cases were reported in conjunction with J&J.
    280 reports of Guillain-Barré Syndrome with 46% of cases attributed to Pfizer, 40% to Moderna and 20% to J&J.
    83,684 reports of anaphylaxis with 40% of cases attributed to Pfizer’s vaccine, 51% to Moderna and 9% to J&J.
    5,159 reports of blood clotting disorders. Of those, 2,213 reports were attributed to Pfizer, 1,617 reports to Moderna and 1,289 reports to J&J.
    Seven cases of heart inflammation reported in teen boys, new study shows
    On June 4, The Defender reported seven boys between the ages of 14 and 19 in the U.S. reportedly developed chest pain and heart inflammation within four days of receiving a second dose of the Pfizer vaccine, according to a study published today in Pediatrics.
  • T
    T.
    Supreme court refuses to hear $2 billion damages case, market cap down by $4+ billion. Makes no sense. Will recover.
  • R
    Rob
    JNJ looking better and better
    CDC To Hold "Emergency Meeting" After 100s Suffer Heart Inflammation Following COVID Vaccines
    The Centers for Disease Control and Prevention announced Thursday that it will convene an "emergency meeting" of its advisers on June 18th to discuss rare but higher-than-expected reports of heart inflammation following doses of the mRNA-based Pfizer and Moderna COVID-19 vaccines.
    Bullish
  • R
    RJH
    anyone know why stock is down so much today? Is there any news?